Ac Immune News Today

We can readily understand why investors are attracted to unprofitable companies. For example, although...

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming p...

AC Immune SA (NASDAQ:ACIU – Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 480,600 shares, a drop of 14.1% from the January 15th total of 559,300 shares. Based on an average daily trading volume, of 127,500 […]

Shares of AC Immune SA (NASDAQ:ACIU – Get Free Report) traded up 13.8% during trading on Monday . The company traded as high as $4.92 and last traded at $4.87. 277,917 shares were traded during trading, an increase of 51% from the average session volume of 184,616 shares. The stock had previously closed at $4.28. […]

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical A...

AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering...

AC Immune SA (NASDAQ:ACIU – Get Free Report) fell 6.2% during trading on Tuesday . The stock traded as low as $3.50 and last traded at $3.62. 99,878 shares were traded during mid-day trading, a decline of 70% from the average session volume of 336,394 shares. The stock had previously closed at $3.86. Analyst Ratings […]

By Colin Kellaher AC Immune has named Christopher Roberts chief financial officer, removing the interim tag he has carried since early 2022. The Lausanne,...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023...